For the year ending 2025-12-31, XCUR had -$8,762K decrease in cash & cash equivalents over the period. -$8,556K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -4,946 |
| Depreciation and amortization | 242 |
| Amortization of right-of-use asset | 218 |
| Equity-based compensation | 2 |
| Right-of-use asset impairment loss | 0 |
| Change in fair value of contingent consideration | 1,553 |
| Gain on early lease termination | 5,974 |
| Gain on settlement of accounts payables | 346 |
| Loss on disposal/sale of subsidiary | -98 |
| Loss from sale of property and equipment | -90 |
| Income tax benefit | -634 |
| Accounts receivable | -1,342 |
| Prepaid expenses and other current assets | -39 |
| Other noncurrent assets | -198 |
| Accounts payable | 177 |
| Accrued expenses | -614 |
| Other liabilities | 0 |
| Net cash used in operating activities | -8,555 |
| Capital expenditures | 1 |
| Proceeds from sale of fixed assets | 42 |
| Acquisition of gpcr therapeutics usa inc | 2,090 |
| Proceeds from sale of subsidiary | 474 |
| Cash removed from the sale of kcc | 232 |
| Net cash used in by investing activities | -1,807 |
| Proceeds from sale of common stock | 1,600 |
| Proceeds from short term debt | 0 |
| Net cash provided by financing activities | 1,600 |
| Net (decrease) in cash, cash equivalents, and restricted cash | -8,762 |
| Cash, cash equivalents, and restricted cash - beginning of year | 12,508 |
| Cash, cash equivalents, and restricted cash - end of year | 3,746 |
EXICURE, INC. (XCUR)
EXICURE, INC. (XCUR)